HRP20161344T1 - Novi citostatski 7-deazapurinski nukleozidi - Google Patents
Novi citostatski 7-deazapurinski nukleozidi Download PDFInfo
- Publication number
- HRP20161344T1 HRP20161344T1 HRP20161344TT HRP20161344T HRP20161344T1 HR P20161344 T1 HRP20161344 T1 HR P20161344T1 HR P20161344T T HRP20161344T T HR P20161344TT HR P20161344 T HRP20161344 T HR P20161344T HR P20161344 T1 HRP20161344 T1 HR P20161344T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- alkyl
- halo
- heteroaryl
- hydrogen
- Prior art date
Links
- 239000000824 cytostatic agent Substances 0.000 title 1
- 230000001085 cytostatic effect Effects 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 125000003835 nucleoside group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- -1 selenophenyl Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
- H02J7/00032—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by data exchange
- H02J7/00036—Charger exchanging data with battery
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
- H02J7/00047—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries with provisions for charging different types of batteries
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Power Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (13)
1. Spoj s formulom I:
[image]
naznačen time da:
R1 je (C1-C6)alkil, hidroksi(C1-C6)alkil, aril, aril(C1-C6)alkil, heteroaril koji se bira iz skupa koji sadrži furanil, tienil, pirolil, tiazoil, imidazolil, piridil, selenofenil, ili pirazolil, ili heteroaril(C1-C6)alkil, pri čemu svaki aril ili heteroaril je proizvoljno supstituiran s jednom ili više skupina koje se biraju od (C1-C6)alkil, (C1-C6)alkoksi, (C1-C6)alkiltio, halo, amino, nitro, cijano, trifluorometil, ili hidroksi; te
R2 je vodik, heteroaril, halo, ili aril koji je proizvoljno supstituiran s jednom ili više skupina koje se biraju od (C1-C6)alkil, (C1-C6)alkoksi, (C1-C6)alkiltio, halo, amino, nitro, cijano, trifluorometil, ili hidroksi;
ili njihova sol;
uz uvjet da kada R1 je nesupstituirani fenil, R2 nije vodik.
2. Spoj prema zahtjevu 1, naznačen time da R1 je heteroaril.
3. Spoj prema zahtjevu 1, naznačen time da R1 je furanil, tienil, pirolil, tiazoil, imidazolil, piridil, selenofenil, ili pirazolil.
4. Spoj prema zahtjevu 1, naznačen time da R1 je 5-člani heteroaril, ili hidroksil-( C1-C4)alkil, R2 je vodik, ili halo; ili njihova sol.
5. Spoj prema zahtjevu 1, naznačen time da R1 je furanil, tienil, pirolil, tiazoil, imidazolil, piridil, selenofenil, ili pirazolil, R2 je vodik ili halo, ili njihova sol.
6. Spoj prema zahtjevu 5, naznačen time da R2 je vodik.
7. Spoj prema zahtjevu 5, naznačen time da R2 je halo.
8. Spoj prema bilo kojem od zahtjeva 1 do 7 naznačen time da je za uporabu za inhibiciju rasta tumora/raka kod subjekta.
9. Spoj prema bilo kojem od zahtjeva 1 do 7 naznačen time da je za uporabu za inhibiciju proliferacije stanice kod stanica tumora/raka kod subjekta.
10. Spoj prema bilo kojem od zahtjeva 1 do 7 naznačen time da je za uporabu za liječenje stanične proliferacijske bolesti kod subjekta.
11. Spoj prema bilo kojem od zahtjeva 1 do 7 naznačen time da je za uporabu za liječenje neoplastične bolesti kod subjekta.
12. Spoj prema bilo kojem od zahtjeva 1 do 7 naznačen time da je za uporabu za liječenje tumor ili raka kod subjekta.
13. Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 7 i jedan ili više farmaceutski prihvatljivih nosača.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2224708P | 2008-01-18 | 2008-01-18 | |
| PCT/CZ2009/000004 WO2009089804A1 (en) | 2008-01-18 | 2009-01-15 | Novel cytostatic 7-deazapurine nucleosides |
| EP09702842.7A EP2231689B1 (en) | 2008-01-18 | 2009-01-15 | Novel cytostatic 7-deazapurine nucleosides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161344T1 true HRP20161344T1 (hr) | 2016-11-18 |
Family
ID=40434932
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161344TT HRP20161344T1 (hr) | 2008-01-18 | 2016-10-14 | Novi citostatski 7-deazapurinski nukleozidi |
| HRP20181774TT HRP20181774T1 (hr) | 2008-01-18 | 2018-10-29 | Novi citostatski 7-deazapurinski nukleosidi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181774TT HRP20181774T1 (hr) | 2008-01-18 | 2018-10-29 | Novi citostatski 7-deazapurinski nukleosidi |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8093226B2 (hr) |
| EP (2) | EP2231689B1 (hr) |
| JP (2) | JP5485172B2 (hr) |
| CN (1) | CN101977923B (hr) |
| AU (1) | AU2009204568B2 (hr) |
| CA (1) | CA2711384C (hr) |
| CY (2) | CY1118104T1 (hr) |
| DK (2) | DK2231689T3 (hr) |
| ES (2) | ES2598503T3 (hr) |
| HR (2) | HRP20161344T1 (hr) |
| HU (2) | HUE041598T2 (hr) |
| LT (2) | LT3133080T (hr) |
| NZ (1) | NZ586610A (hr) |
| PL (2) | PL3133080T3 (hr) |
| PT (2) | PT2231689T (hr) |
| SI (2) | SI3133080T1 (hr) |
| TR (1) | TR201815961T4 (hr) |
| WO (1) | WO2009089804A1 (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA98449C2 (en) | 2005-12-13 | 2012-05-25 | Инсайт Корпорейшин | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| RS53245B2 (sr) | 2007-06-13 | 2022-10-31 | Incyte Holdings Corp | Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| SI2421879T1 (sl) * | 2009-04-22 | 2014-01-31 | Institute Of Organic Chemistry And Biochemistry As Cr | Novi 7-deazapurinski nukleozidi za terapevtske uporabe |
| LT2432472T (lt) * | 2009-05-22 | 2020-02-10 | Incyte Holdings Corporation | 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai |
| BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| AU2011224484A1 (en) | 2010-03-10 | 2012-09-27 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| CN103002875B (zh) | 2010-05-21 | 2016-05-04 | 因塞特控股公司 | Jak抑制剂的局部用制剂 |
| EP2640392B1 (en) * | 2010-11-18 | 2015-01-07 | Kasina Laila Innova Pharmaceuticals Private Ltd. | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| AR086983A1 (es) | 2011-06-20 | 2014-02-05 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| MY191357A (en) | 2012-11-15 | 2022-06-19 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| UA120162C2 (uk) | 2013-03-06 | 2019-10-25 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки при отриманні інгібітора jak |
| PT3030227T (pt) | 2013-08-07 | 2020-06-25 | Incyte Corp | Formas de dosagem de libertação prolongada para um inibidor de jak1 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| US10414788B2 (en) | 2016-06-29 | 2019-09-17 | Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. | Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use |
| CZ307334B6 (cs) | 2016-08-02 | 2018-06-13 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| KR20200129099A (ko) | 2018-01-30 | 2020-11-17 | 인사이트 코포레이션 | (1-(3-플루오로-2-(트리플루오로메틸)이소니코티닐)피페리딘-4-온)의 제조 방법 |
| CZ308104B6 (cs) | 2018-03-12 | 2020-01-08 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. | Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití |
| CN112423759A (zh) | 2018-03-30 | 2021-02-26 | 因赛特公司 | 使用jak抑制剂治疗化脓性汗腺炎 |
| US20220152072A1 (en) * | 2019-04-05 | 2022-05-19 | Prelude Therapeutics, Incorporated | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) |
| BR112021025341A2 (pt) * | 2019-06-18 | 2022-02-01 | Taiho Pharmaceutical Co Ltd | Compostos de carbonato tendo esqueleto de pirrolopirimidina ou sal farmaceuticamente aceitável dos mesmos, agentes antitumorais e composições farmacêuticas compreendendo os ditos compostos, bem como usos e usos terapêuticos dos mesmos |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN112190590A (zh) * | 2020-11-06 | 2021-01-08 | 牡丹江医学院 | 一种治疗动脉粥样硬化的硒核苷及其药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS50125033A (hr) * | 1974-03-19 | 1975-10-01 | ||
| IL108523A0 (en) | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| JPH10158293A (ja) * | 1996-08-08 | 1998-06-16 | Rikagaku Kenkyusho | ３’−デオキシリボヌクレオチド誘導体 |
| JP3489991B2 (ja) * | 1997-07-07 | 2004-01-26 | 理化学研究所 | ３’−デオキシリボヌクレオチド誘導体 |
| JP3318579B2 (ja) * | 1997-07-07 | 2002-08-26 | 理化学研究所 | Ｄｎａの塩基配列決定方法 |
| CZ9901996A3 (cs) * | 1999-06-04 | 2001-01-17 | Ústav organické chemie a biochemie AV ČR | Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují |
| AU2002353165A1 (en) * | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
| WO2005021568A2 (en) * | 2003-08-27 | 2005-03-10 | Biota, Inc. | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
| US20080280842A1 (en) * | 2004-10-21 | 2008-11-13 | Merck & Co., Inc. | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection |
| WO2006116557A1 (en) * | 2005-04-25 | 2006-11-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
-
2009
- 2009-01-15 PL PL16174985T patent/PL3133080T3/pl unknown
- 2009-01-15 ES ES09702842.7T patent/ES2598503T3/es active Active
- 2009-01-15 US US12/354,432 patent/US8093226B2/en active Active
- 2009-01-15 PT PT97028427T patent/PT2231689T/pt unknown
- 2009-01-15 WO PCT/CZ2009/000004 patent/WO2009089804A1/en active Application Filing
- 2009-01-15 HU HUE16174985A patent/HUE041598T2/hu unknown
- 2009-01-15 PT PT16174985T patent/PT3133080T/pt unknown
- 2009-01-15 SI SI200931882T patent/SI3133080T1/sl unknown
- 2009-01-15 EP EP09702842.7A patent/EP2231689B1/en active Active
- 2009-01-15 LT LTEP16174985.8T patent/LT3133080T/lt unknown
- 2009-01-15 HU HUE09702842A patent/HUE030767T2/en unknown
- 2009-01-15 DK DK09702842.7T patent/DK2231689T3/en active
- 2009-01-15 AU AU2009204568A patent/AU2009204568B2/en active Active
- 2009-01-15 EP EP16174985.8A patent/EP3133080B1/en active Active
- 2009-01-15 CN CN200980109880.3A patent/CN101977923B/zh active Active
- 2009-01-15 LT LTEP09702842.7T patent/LT2231689T/lt unknown
- 2009-01-15 ES ES16174985.8T patent/ES2693551T3/es active Active
- 2009-01-15 DK DK16174985.8T patent/DK3133080T3/en active
- 2009-01-15 NZ NZ586610A patent/NZ586610A/xx unknown
- 2009-01-15 SI SI200931535A patent/SI2231689T1/sl unknown
- 2009-01-15 CA CA2711384A patent/CA2711384C/en active Active
- 2009-01-15 PL PL09702842T patent/PL2231689T3/pl unknown
- 2009-01-15 JP JP2010542509A patent/JP5485172B2/ja active Active
- 2009-01-15 TR TR2018/15961T patent/TR201815961T4/tr unknown
-
2013
- 2013-12-25 JP JP2013266910A patent/JP2014058567A/ja not_active Withdrawn
-
2016
- 2016-10-14 HR HRP20161344TT patent/HRP20161344T1/hr unknown
- 2016-10-19 CY CY20161101041T patent/CY1118104T1/el unknown
-
2018
- 2018-10-29 HR HRP20181774TT patent/HRP20181774T1/hr unknown
- 2018-10-30 CY CY20181101120T patent/CY1121364T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161344T1 (hr) | Novi citostatski 7-deazapurinski nukleozidi | |
| HRP20210365T1 (hr) | Dna-pk inhibitori | |
| JP2011509949A5 (hr) | ||
| HRP20191979T1 (hr) | Heteoarilni spojevi koji su korisni kao inhibitori sumo-aktivirajućeg enzima | |
| HRP20170627T1 (hr) | Derivati 2-metilmorfolin pirido-, pirazo- i pirimido-pirimidina kao inhibitori mtor | |
| HRP20161103T1 (hr) | Kemijski spojevi | |
| IL276711B2 (en) | Arginase inhibitors and methods of using them | |
| WO2007048066A3 (en) | Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators | |
| EA201001368A1 (ru) | Гетероциклические производные мочевины и способы их применения-211 | |
| HRP20160654T1 (hr) | 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA | |
| MX2009011997A (es) | Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos. | |
| HRP20131021T1 (hr) | Novi 7-deazapurin nukleozidi za terapijske uporabe | |
| MX2009011579A (es) | Pirimidinonas como moduladores de caseina cinasa ii (ck2). | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| PE20081806A1 (es) | Imidazo- y triazolopirimidinas sustituidas | |
| MX2010006799A (es) | Benzofuropirimidinonas como inhibidores de la proteina cinasa. | |
| WO2009016460A3 (en) | Pyrazole compounds and their use as raf inhibitors | |
| BRPI0818893B8 (pt) | compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula | |
| JP2016504365A5 (hr) | ||
| MY151986A (en) | Adamantyl diamide derivatives and uses of same | |
| NZ598294A (en) | Heterocyclic compounds for the inhibition of pask | |
| WO2006095159A8 (en) | (imidazolo-5-yl)-2-anilo-pyrimidines as agents for the inhibition of cell proliferation | |
| MX2010003156A (es) | Derivados de aril amida substituida con tetrazol y usos de los mismos. | |
| MY156552A (en) | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | |
| TW200643013A (en) | Pyrazoles |